PMID- 27460087
OWN - NLM
STAT- MEDLINE
DCOM- 20170207
LR  - 20181113
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 37
IP  - 10
DP  - 2016 Oct
TI  - Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors.
PG  - 12991-13003
AB  - Well-differentiated bronchial neuroendocrine tumors (B-NETs) are rare. They 
      represent 1-5 % of all lung cancers. The incidence of these neoplasms has risen 
      over the past 30 years and, especially for advanced or metastatic disease, 
      management is complex and requires a multidisciplinary approach. Treatment with 
      somatostatin analogs (SSAs) is the most important first-line therapy, in 
      particular in well-differentiated NETs with high somatostatin type receptor 
      (SSTR) expression. In these tumors, the role of mammalian target of rapamycin 
      (m-TOR) inhibitors and the potential utility of other target therapies remain 
      unclear while chemotherapy represents the gold standard treatment only for 
      aggressive forms with low SSTR expression. Peptide receptor radionuclide therapy 
      (PRRT) is an emerging treatment modality for advanced NETs. There are many 
      cumulative evidences about the effectiveness and tolerability of this therapeutic 
      approach, especially in gastro-entero-pancreatic (GEP)-NETs. For B-NETs, 
      scientific research is moving more slowly. Here, we performed a review in order 
      to evaluate the efficacy and toxicity of PRRT with a focus on patients with 
      inoperable or metastatic well-differentiated B-NETs.
FAU - Lo Russo, Giuseppe
AU  - Lo Russo G
AD  - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Via Giacomo Venezian 1, Milan, Italy. giuseppe.lorusso@istitutotumori.mi.it.
FAU - Pusceddu, Sara
AU  - Pusceddu S
AD  - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Via Giacomo Venezian 1, Milan, Italy.
FAU - Prinzi, Natalie
AU  - Prinzi N
AD  - Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
FAU - Imbimbo, Martina
AU  - Imbimbo M
AD  - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Via Giacomo Venezian 1, Milan, Italy.
FAU - Proto, Claudia
AU  - Proto C
AD  - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Via Giacomo Venezian 1, Milan, Italy.
FAU - Signorelli, Diego
AU  - Signorelli D
AD  - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Via Giacomo Venezian 1, Milan, Italy.
FAU - Vitali, Milena
AU  - Vitali M
AD  - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Via Giacomo Venezian 1, Milan, Italy.
FAU - Ganzinelli, Monica
AU  - Ganzinelli M
AD  - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Via Giacomo Venezian 1, Milan, Italy.
FAU - Maccauro, Marco
AU  - Maccauro M
AD  - Department of Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Milan, Italy.
FAU - Buzzoni, Roberto
AU  - Buzzoni R
AD  - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Via Giacomo Venezian 1, Milan, Italy.
FAU - Seregni, Ettore
AU  - Seregni E
AD  - Department of Nuclear Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Milan, Italy.
FAU - de Braud, Filippo
AU  - de Braud F
AD  - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      University of Milan, Milan, Italy.
FAU - Garassino, Marina Chiara
AU  - Garassino MC
AD  - Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 
      Via Giacomo Venezian 1, Milan, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160727
PL  - Netherlands
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental 
      Biology and Medicine
JID - 8409922
RN  - 0 (Radiopharmaceuticals)
RN  - 0 (Receptors, Peptide)
RN  - 0 (Receptors, Somatostatin)
SB  - IM
MH  - Bronchial Neoplasms/metabolism/pathology/*radiotherapy
MH  - Humans
MH  - Neuroendocrine Tumors/metabolism/pathology/*radiotherapy
MH  - Radiopharmaceuticals/*therapeutic use
MH  - Receptors, Peptide/*metabolism
MH  - Receptors, Somatostatin/*metabolism
OTO - NOTNLM
OT  - Bronchial neuroendocrine tumors
OT  - Lung carcinoids
OT  - Neuroendocrine tumors
OT  - Peptide receptor radionuclide therapy
EDAT- 2016/07/28 06:00
MHDA- 2017/02/09 06:00
CRDT- 2016/07/28 06:00
PHST- 2016/04/07 00:00 [received]
PHST- 2016/07/15 00:00 [accepted]
PHST- 2016/07/28 06:00 [pubmed]
PHST- 2017/02/09 06:00 [medline]
PHST- 2016/07/28 06:00 [entrez]
AID - 10.1007/s13277-016-5258-9 [pii]
AID - 10.1007/s13277-016-5258-9 [doi]
PST - ppublish
SO  - Tumour Biol. 2016 Oct;37(10):12991-13003. doi: 10.1007/s13277-016-5258-9. Epub 
      2016 Jul 27.